Correlation of CTNNB1 Mutation Status with Progression Arrest Rate in RECIST Progressive Desmoid-Type Fibromatosis Treated with Imatinib: Translational Research Results from a Phase 2 Study of the German Interdisciplinary Sarcoma Group (GISG-01)

2016 ◽  
Vol 23 (6) ◽  
pp. 1924-1927 ◽  
Author(s):  
Bernd Kasper ◽  
Viktor Gruenwald ◽  
Peter Reichardt ◽  
Sebastian Bauer ◽  
Peter Hohenberger ◽  
...  
Keyword(s):  
Translational Research ◽  
Phase 2 ◽  
Arrest Rate ◽  
Mutation Status ◽  
Research Results ◽  
Phase 2 Study ◽  
Ctnnb1 Mutation

scholarly journals Relevance of the immunoglobulin VH somatic mutation status in patients with chronic lymphocytic leukemia treated with fludarabine, cyclophosphamide, and rituximab (FCR) or related chemoimmunotherapy regimens

Blood ◽  
2009 ◽  
Vol 113 (14) ◽  
pp. 3168-3171 ◽  
Author(s):  
Katherine I. Lin ◽  
Constantine S. Tam ◽  
Michael J. Keating ◽  
William G. Wierda ◽  
Susan O'Brien ◽  
...  
Keyword(s):  
Chronic Lymphocytic Leukemia ◽  
Somatic Mutation ◽  
Alkylating Agents ◽  
Single Agent ◽  
Multivariate Model ◽  
Lymphocytic Leukemia ◽  
Phase 2 ◽  
Mutation Status ◽  
Phase 2 Study ◽  
Baseline Characteristics

AbstractAlthough immunoglobulin VH mutation status (IgVH MS) is prognostic in patients with chronic lymphocytic leukemia (CLL) who are treated with alkylating agents or single-agent fludarabine, its significance in the era of chemoimmunotherapy is not known. We determined the IgVH somatic mutation status (MS) in 177 patients enrolled in a phase 2 study of fludarabine, cyclophosphamide, and rituximab (FCR) and in 127 patients treated with subsequent chemoimmunotherapy protocols. IgVH MS did not impact significantly on the complete remission (CR) rate of patients receiving FCR or related regimens. However, CR duration was significantly shorter in patients with CLL that used unmutated IgVH than those whose CLL used mutated IgVH (TTP 47% vs 82% at 6 years, P < .001). In a multivariate model considering all baseline characteristics, IgVH MS emerged as the only determinant of remission duration (hazard ratio 3.8, P < .001). Our results suggest that postremission interventions should be targeted toward patients with unmutated IgVH status.

Efficacy, Health-Related Outcomes, and Safety of Ixekizumamb for up to Five Years of Open-Label Treatment in a Phase 2 Study in Chronic Plaque Psoriasis

2017 ◽  
Vol 1 ◽  
pp. s12
Author(s):  
Andrew Blauvelt ◽  
Craig Leonardi ◽  
Claus Zachariae ◽  
Russel Burge ◽  
Terri Ridenour ◽  
...  
Keyword(s):  
Plaque Psoriasis ◽  
Phase 2 ◽  
Chronic Plaque Psoriasis ◽  
Open Label ◽  
Phase 2 Study ◽  
Health Related

Abstract Not Available

Sign in / Sign up

Export Citation Format

Share Document